Data
from the PrimoTinA-asthmaTM Phase III research studies presented for the very
first time today with the 2012 European Respiratory Society (ERS) congress
illustrate that tiotropium significantly lowered asthma exacerbations in
affected individuals who remain characteristic despite therapy which have at
the very least ICS/LABA.
Tiotropium
also substantially enhanced lung function in characteristic asthma patients on
ICS/LABA.
Professor
Huib A M Kerstjens of the University Medical Centre, Groningen, The
Netherlands, and lead author on both studies, said: "Each of these results
surpassed our predictions. While we were waiting enhancements in lung function
when introducing tiotropium to traditional care, the numerous lowering of the
risk of exacerbations came being a surprise - especially given that each one
affected individuals were usually already receiving optimal preservation
therapy as described by the GINA guidelines."
There
were also large enhancements in asthma control and asthma associated standard
living (evaluated by the questionnaires ACQ and AQLQ) in one trial, as well as trends
towards development in asthma manage in the other trial.
Despite
current methods of treatment, there is an unmet medical need in asthma, as a
significant proportion of affected individuals remains symptomatic and may
possibly experience asthma exacerbations.
No comments:
Post a Comment